-
The jumping breast phenomenon is well known in cosmetic surgery but there is hardly any literature about it. In oncological breast surgery, the problem has even been mostly ignored so far, although the deformation of the breast is sometimes serious and the patients suffer considerably from it.
-
The kick-off day of the 10th International Charité Mayo Conference, staged a keynote lecture by Adrian Lee from Pittsburgh, USA, who has a key role in the design of precision medicine.
-
Overuse, misuse and also the almost exponential use of antibiotics in animal production contribute to antibiotic resistance. Important medications may no longer be usable in the future. The search for antibiotics alternatives has therefore long ago begun.
-
The placement of a stent is a routine task for urologists worldwide. The responsibility to remove this stent also rests on their shoulders. Statistically, however, about 13% of stents are forgotten - with far-reaching consequences for the patients and beyond.
-
Testosterone administration is contraindicated in PCa patients even after radical prostatectomy. But more recent findings in hypogonadal men hint at a slow rehabilitation of testosterone substitution.
-
Urogenital TB is often overlooked. In regions with high TB prevalence, it is "treated" as a classic UTI. UTIs may mask urogenital tuberculosis frequently, and doctors should be reminded of this scenario.
-
Nephrolithiasis is a frequently treated disease in urology, assumed to have no further room for groundbreaking innovations. However, causal research and the vacuum-assisted mini-percutaneous nephrolithotomy (vmPCNL) hint at new developments.
-
Drug interactions are almost impossible to avoid in the care of HIV patients, said David Back, University of Liverpool. The risk for polypharmacy and thus for interactions increases with age due to increased comorbidities and physiological changes.
-
Obesity has many consequences for the health of those affected. John R. Koethe, Vanderbilt University Medical Center, Nashville, TN, USA, presented the current state of research at the CROI 2019.
-
With only a few studies available, the current WHO recommendations are mainly based on observations. Jennifer Furin, Harvard Medical School, USA, presented current developments in MDR-TB treatments.
-
Latent HI viruses are the first target of the so-called shock-and-kill strategy. As part of this strategy, latency is eliminated by Latency Reversing Agents (LRAs).
-
HIV-positive men who have sex with men (MSM) are particularly affected, but HIV-negative men are also becoming increasingly infected. Although the therapy is expensive, it is highly effective, preventative and overall cost-efficient when used early.
-
Jeffrey Cohen, National Institute of Allergy and Infectious Diseases, USA, reported on the current developments pertaining to the development of vaccine options against the Epstein-Barr virus.
-
Kaposi's sarcoma-associated herpesvirus (KSHV) can modulate the innate immune response by producing various proteins. Damania Blossom, from the University of North Carolina, Chapel Hill, USA, presented experimental data at the CROI 2019.
-
Drug therapy for pregnant women is a balancing act between maternal treatment and the possible harm to the unborn child. Lynne Meryl Mofenson (Elizabeth Glaser Pediatric AIDS Foundation, USA) presented the most recent research on antiretroviral agents treatments for pregnant women.
-
Mark R. Pakianathan, from the School of Hygiene and Tropical Medicine, St. George's University of London, addressed the role of Chemsex in the spread of sexually transmitted infections (STI), hepatitis C and especially HIV.
-
The Musculoskeletal Working Group on Hemophilia brought together experts to develop guidelines about "Synovitis in Hemophilia". The determination of the trough level, i.e. the factor level immediately before the next injection, and patient adherence are relevant for prophylaxis.
-
Results from the randomized prophylaxis phase III PROPEL study were presented. The study shows zero rates of total bleeding and spontaneous joint bleeding that have not been reported by people with hemophilia A before.
-
At the 63rd Annual Meeting of the Society for Thrombosis and Haemostasis Research, Florian Langer, Hamburg, and Martin Grünewald discussed the pros and cons of using DOACs in tumor-associated VTE.
-
Some hemophilia patients develop antibodies against the coagulation factors administered during therapy. To remove such so-called inhibitors, immunotolerance therapy has been used. This, however, is expensive, painful and often has limited effectiveness.
